Several immunotherapy approaches designed to initiate anti-tumor immune response were shown to activate the cGAS-STING pathway and the therapeutic effects of the treatments are correlated with the STING expression within the tumor microenvironment (Corrales and Gajewski 2015). Here, STING1 is linked to neoplasm.